Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
Authors:
- A. F. HottingerAHA. F. Hottinger
- S. KarimiSKS. Karimi
- E. RiedelERE. Riedel
- J. DantisJDJ. Dantis
- M. JahdiMJM. Jahdi
- K. S. PanageasKPK. S. Panageas
- A. B. LassmanALA. B. Lassman
- L. E. AbreyLAL. E. Abrey
- M. FleisherMFM. Fleisher
- L. M. DeAngelisLDL. M. DeAngelis
- E. C. HollandEHE. C. Holland
- 10 August 2011
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (11) , 1244-1251
Abstract
The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans at multiple time points during the course of the disease. YKL-40 levels determined by ELISA were correlated with radiographic disease status and survival. We performed a multivariate survival analysis including well-known prognostic factors such as age, performance status, and extent of surgical resection. Three hundred and forty-three patients with gliomas (41 low-grade, 105 anaplastic, and 197 glioblastoma) were accrued. Two-year survival from registration was 29% for glioblastomas, 62% for anaplastic gliomas, and 83% for low-grade gliomas. A total of 1740 serum samples were collected, and 95.6% of samples had matching MRI scans. Serum YKL-40 level was significantly lower in patients with no radiographic disease compared with patients with radiographic disease in both the anaplastic glioma (P= .0008) and the glioblastoma (P= .0006) cohorts. Serum levels of YKL-40 in patients with low-grade gliomas were not associated with radiographic disease status. Increases in YKL-40 were independently associated with worse survival in anaplastic gliomas (hazard ratio [HR] = 1.4, P= .01) and glioblastomas (HR = 1.4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients.Keywords
This publication has 34 references indexed in Scilit:
- Response criteria for gliomaNature Clinical Practice Oncology, 2008
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Integrated Array-Comparative Genomic Hybridization and Expression Array Profiles Identify Clinically Relevant Molecular Subtypes of GlioblastomaCancer Research, 2005
- High serum YKL-40 level in patients with small cell lung cancer is related to early deathLung Cancer, 2004
- Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40Journal of Clinical Oncology, 2004
- High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- An overview of methods for the analysis of longitudinal dataStatistics in Medicine, 1992
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990